Advertisement
![Picture [iito] Life Science Business Portals Media Data 2022 2 650x100px](/banner/iito-business-intelligence-20220401-650-100-promote-brand-to-decision-makers.jpg)
Document › Details
Semalytix GmbH. (11/24/20). "Press Release: Corporate Vice President of Bayer Pharmaceuticals Becomes Advisor to Semalytix". Bielefeld.
![]() |
Organisation | Semalytix GmbH |
Organisation 2 | Bayer Pharmaceuticals Corporation | |
Group | Bayer (Group) | |
![]() |
Product | AI-based clinical research |
Product 2 | drug development | |
![]() |
Person | Jaskolski, Janik (Semalytix 201505– Managing Director + Co-Founder) |
Semalytix announced today that Frank Misselwitz, Corporate Vice President of Bayer Pharmaceuticals, is supporting the company in the role of an advisor.
“I am extremely proud to announce today that Frank Misselwitz, Corporate VP of Bayer Pharmaceuticals, will support Semalytix in an advisor role to further our mission to make Patient Centricity a true Northstar KPI in drug development.” says Janik Jaskolski, CEO and co-founder of Semalytix.
Frank Misselwitz brings extensive experience in clinical trial execution and drug development to the company, and will provide strategic guidance to the creation of AI technology that uncovers unknown patient needs to generate the deepest possible understanding of how humans suffer from disease. The company’s ultimate goal is to generate patient experience insights on a greater scale and with more ease for new therapies and to improve the quality of care for billions: one disease at a time.
contact: Jannis Johannmeier
phone: +49(0) 172 5270504
email: press@semalytix.com
web: semalytix.com
Record changed: 2022-02-05 |
Advertisement
![Picture [iito] Männer Ballett 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-maenner-ballett.jpg)
More documents for Semalytix GmbH
- [1] CMS. (9/7/20). "Pressemitteilung: CMS begleitet Gründer des KI Start-ups Semalytix bei Serie-A Finanzierungsrunde". Berlin....
- [2] Semalytix GmbH. (8/31/20). "Press Release: Semalytix Closes Series A Investment Totaling €4.3m"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top